Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06647238 · ClinicalTrials.gov registry record · NA
Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention
A NA study of Coronary Artery Disease and Hyperlipidemia, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06647238: Completed NA study of Coronary Artery Disease and Hyperlipidemia, sponsored by Wake Forest University Health Sciences.
NCT06647238 is a NA study of Coronary Artery Disease and Hyperlipidemia that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 80 participants, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06647238, a NA study of Coronary Artery Disease and Hyperlipidemia, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.
Primary Outcome
patients with LDL within goal (\<55) (yes/no)
Conditions Studied
Interventions
- OTHER Pharmacist Intervention in lipid therapy
Study Locations (1)
North Carolina
- Atrium Health Cabarrus - Concord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-11-05 |
| Est. Completion | 2025-05-27 |
| Phase | NA |
What the finished NCT06647238 record still lists
NCT06647238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,287-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Pharmacist Intervention in lipid therapy is the first listed.
NCT06647238 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06647238 about?
NCT06647238 is a clinical study titled "Evaluation of Pharmacist Interventions in Lipid Management for Secondary Prevention". The primary objective of this research project is to compare the effect of pharmacist interventions versus usual care in the implementation of guideline directed lipid lowering therapies for secondary prevention.
What is the current status of trial NCT06647238?
This trial is currently completed. It is a NA study. The enrollment target is 80 participants. The study started on 2024-11-05. Estimated completion is 2025-05-27.
What conditions does trial NCT06647238 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Hyperlipidemia.
What interventions are being tested in trial NCT06647238?
The interventions under investigation include: Pharmacist Intervention in lipid therapy (OTHER).
Who is sponsoring clinical trial NCT06647238?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06647238 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06647238's enrollment target sits among peer trials
80 158th of 219 higher than 61 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
-
Intravascular Lithotripsy With or Without Rotational Atherectomy for Coronary Calcified Nodule Treatment
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI